Biotime

[Paulness]

ACTC looks to hold the patents to IPS cells

http://www.scimitarequity.com/blog/2010/08/17/ips-cell-patents-advanced-cell-technology-actc-ob/

[DrStrangelove]

The Bollinger bands are really pinching on the charts now so I expect a big move soon. Let's hope it's UP!

[pumpnass]

i am sure DR West is the one i want in my corner he is making all the right moves and it will soon pay off 10 fold ;o)

[read_this_n0w]

Those are different technologies based on creating stemcell lines.Those still would have to be stored or kept in good condition, pktx compound has much smaller aspirations and is only supportive to stem cell uses.


I do own BTX btw in longterm portfolio, do like their acquiring strategy and their tech as well. Think its one of the stronger companies out there. Price wise quite decent climb allready on the weekly charts.

[pumpnass]

maybe this could help you

BioTime, Inc. (NYSE AMEX: BTIM) is a biotechnology company engaged in two areas of biomedical research and product development:


Stem cell technology and products for use in regenerative medicine. These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.

Blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications. Our lead product is Hextend® which is being marketed by Hospira, Inc. and CJ CheilJedang Corp. under exclusive licenses from us
The Potential of Regenerative Medicine

Regenerative medicine refers to therapies based on human embryonic stem (“hES”) cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The great scientific and public interest in regenerative medicine lies in the potential of hES cells to transform into any cell type of the human body. hES cells therefore show considerable potential as a source of new therapies for a host of currently-incurable diseases such as: diabetes, stroke, Alzheimer’s and Parkinson’s disease, heart failure, arthritis, muscular dystrophy, spinal cord injury, macular degeneration, hearing loss, kidney and liver failure, as well as many other disorders that may be treated by replacing diseased or damaged organ tissues. In response to the unusual potential of the field, the State of California has allocated $3 billion over the next 10 years to fund basic research, and President Obama has lifted previous restrictions for federal funding of stem cell research.

Led by Dr. Michael West, considered by many to be a founding father of the stem cell industry, BioTime has assembled an array of products and associated intellectual property that give it the potential to be a leader in this exciting new field of medicine.

We are implementing a near-term revenues strategy in the regenerative medicine field by seeking to develop and market advanced hES products and technology that can be used by researchers at universities and biopharmaceutical companies. These research-only products generally can be marketed without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to human therapeutic products. We may also initiate development programs for human therapeutic applications if sufficient capital becomes available to us or through joint efforts with industry partners.

BioTime is leveraging its product development strategy on two key technology platforms:


• An advanced iPS technology allowing the transformation of human cells of the body back to a primordial stem cell state equivalent to embryonic stem cells. Using this technology with patient specific stem cells, rather than stem cells derived from embryos donated by unrelated people, may reduce the incidence of rejection of tissue grafts.

ACTCellerate™ technology that permits the generation of scalable and highly purified cells of the human body.
iPS Technology

In July, 2008, BioTime announced the license of a portfolio of patents and patent applications relating to induced pluripotent stem cells (iPS) that may enable the regeneration of human cells without the use of human embryos or cloned viruses. Recent scientific publications have reported the transformation of cells of the human body, such as skin cells, into an embryonic state that gives the cells the potential to transform into any kind of human body cell. Because this new technology does not involve human embryos or egg cells, and classical cloning techniques are not employed, iPS technology is considered an important new avenue in stem cell research. iPS is less controversial than embryonic stem cell technology that relies on cells derived from human embryos, and iPS may be practical for the development of therapeutic cell lines on a commercial scale.

ACTCellerate™ Technology

The power of human embryonic stem cells to become all of the thousands of cell types of the human body is currently challenging the ability of the biotechnology industry to manufacture highly purified and identified cell types as required for the development of clinical-grade therapeutics. BioTime’s ACTCellerateTM technology may be a solution to this challenge by providing a means of delivering large quantities of highly purified cell types.

Our First Stem Cell Products Are Already On the Market

The mission of BioTime’s wholly owned subsidiary Embryome Sciences is to market stem cell products to universities and biomedical companies for research purposes. These products are now being marketed online at http://www.embryome.com. A database providing a detailed map of the “embryome”, aiding researchers in navigating the complexities of the many hundreds of cell types coming from embryonic stem cells, is also being developed at the Embryome.com website.

Our initial products include:

ESpanTM cell growth media, designed for the growth of human embryonic progenitor cells
Approximately 100 progenitor cell types made using the ACTCellerateTM technology
An array of human embryonic stem cell lines carrying inherited genetic diseases such as cystic fibrosis and muscular dystrophy

Embryome Sciences also plans to bring to market:

ESpy™ cell lines, which will be derivatives of hES cells that send beacons of light in response to the activation of particular genes

New growth and differentiation factors that will permit researchers to manufacture specific cell types from embryonic stem cells

Purification tools useful to researchers in quality control of products for regenerative medicine.
As new products are developed, they will become available for purchase at Embryome.com. These cells and related products can be immediately sold into what is estimated to be a $20 billion research market and $80 billion over the next 10 years (Visiongain, 2009). We are also exploring potential opportunities to develop therapeutic applications of our stem cell technologies through collaborations with industry partners.

Hextend® and Other Blood Plasma Expander Products

Our lead blood plasma expander product, Hextend®, is a physiologically balanced intravenous solution used in the treatment of hypovolemia. Hypovolemia is a condition caused by low blood volume, often from blood loss during surgery or from injury. Hextend maintains circulatory system fluid volume and blood pressure and keeps vital organs perfused during surgery and trauma care.

Hextend is the only blood plasma volume expander that contains lactate, multiple electrolytes, glucose, and a medically approved form of starch called hetastarch. Hextend is sterile to avoid risk of infection.

Hextend is part of the U.S. Armed Forces Tactical Combat Casualty Care protocol and is used to treat battlefield casualties. Hextend is also currently being used to treat hypovolemia subsequent to trauma or low blood pressure due to shock by emergency room physicians.

Hextend is being distributed in the United States by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licenses from BioTime. Summit Pharmaceuticals International Corporation has a license to develop Hextend and a companion product PentaLyte® in Japan, the People’s Republic of China, and Taiwan. A Phase III clinical trial is currently underway in Japan.

Intellectual Property and Facilities

BioTime owns or has license to over 200 patents and patent applications relating to stem cell technology allowing us to commercialize the technology described in this summary. This intellectual property includes BioTime’s own technology, as well as patents and patent applications licensed from the Wisconsin Alumni Research Foundation, International Stem Cell Corporation, affiliates of Kirin Pharma Company, Limited, and Advanced Cell Technology.

BioTime has approximately 11,000 square feet of GMP-capable cell and media manufacturing and research laboratories in Alameda, California.

Additional Information

This summary is being provided for informational purposes only, and not for investment purposes. This summary does not contain complete information about BioTime, Inc. and Embryome Sciences, Inc., and does not constitute an offer to sell or a solicitation of an offer to buy any security. Additional information about BioTime and Embryome Sciences can be found in BioTime’s filings with the Securities and Exchange Commission at www.sec.gov or on BioTime’s website at www.biotimeinc.com.

View and download a PDF copy of the above Executive Summary.

http://www.embryome.biz/

[read_this_n0w]

Can you tell me what competing products there are out there to use to increase stem cell yields?

And which are used by BTX or other stemcell companies?
Any opinion on licensing potential?


ProtoKinetix AAGP Dramatically Increase Recovery Rate of Cryopreserved and Refrigerated Stem Cells <PKTX.OB>
newsml:reuters.com

VANCOUVER, British Columbia--(Business Wire)--
ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com), a biotechnology company that
has developed and patented a family of synthetic anti-aging glycopeptides (AAGP)
for medicine and the biotechnology and cosmetic industries today announced, as a
follow up to recent news on the research done by ProtoKinetix` lead scientific
investigator, Dr. Samer Hussein, the Company announces some of his findings as
related to stem cell recovery.

Using a standard cryogenic protocol for stem cell storage, the addition of
2mg/ml of AAGP resulted in an extraordinary recovery of 87-percent. Traditional
recovery rates after cryopreservation with DMSO are typically between 30 and
40-percent.

In addition to the value of AAGP in cryopreservation (frozen to -196?C), a set
of trials designed to determine whether AAGP treated stem cells could survive
after refrigeration (4?C) were conducted. After 3-days of refrigeration,
untreated cells have a very high mortality rate. These trials found that AAGP
can significantly reduce cell death rate. AAGP demonstrated an impressive and
repetitive 8 to 12-times increase in cell viability and survivability.

"Preservation of stem cells is getting to be more and more popular given the
disease fighting regenerative ability of the stem cells. These results with AAGP
opens up an ever expanding market for ProtoKinetix which we fully intend to take
advantage of, said Ross L. Senior, President and CEO of ProtoKinetix, Inc.

[Liquid_Bull]

Back in @ 7.38

[investment_mgr]

I used to own GERN and sold into a spike at 6 and change. I always had a problem with management for starters. That was confirmed a few weeks ago I believe as there was a shakeout in that regard if I am not mistaken.

Also, their ip has been trumped and they have patent problems. I believe BTX actually has a backdoor into GERN's ip through one of their acquisitions, not to mention, much better bis strategies and tech of their own.

GERN became complacent, and simply could not get it done, and the field is passing them by.

BTX and ISCO are the ways to go. I don't own ISCO right now, but did, and will again. I have spec shares in ACTC, but nothing substantial.

I also like CUR, but, not at this time, likely to go lower.

IM

[Liquid_Bull]

Tax free... Roth IRA

[JIMWJ]

After taxes that gets expensive. I try to keep a stock for at least a year. But if that is how you make a buck, have at it.

[Liquid_Bull]

And there it goes... I felt it but I was waiting for 7.90 and refuse to think I will get out at the top or in at any bottom on any stock unless strategically lucky. Greed gets me slaughtered every time, so I am learning to take what I make. When the time is right I will get back in.

[Liquid_Bull]

Back out 1000 @ 7.92 for $625 profit. It could break out here though, I was hesitant to sell. But I decided to lock in $3,500 in profits for the week and BTX was part of those gains. I am looking to get back in...

[pumpnass]

agreed it could go lower but thats just more of a gift for the ones who understand what they hold ;o)

[JIMWJ]

This is a *VERY* good time to buy. This is as low as you will ever see this stock again IMO. Investment firms like the Oxford club are touting this as the next big runner.

[pumpnass]

no doubt bud i was going to say that but i'm happy it came from you. you don't want to get caught with your pants down on this monster ;o)

[Liquid_Bull]

Thanks... just trying to make the little extras in between on the way back up to retesting the highs. Definitely dont like being out of this one, so I am glad to be back in.

[pumpnass]

nice trading bud

[Liquid_Bull]

Back in, 1000 @ 7.28

[Liquid_Bull]

Out @ 7.72 because its up almost a buck on no news. I think I will have a chance to re-enter at my previous buy point. If not, I am happy with locking in my profits after being down.

[Med.rare]

John Mauldin mention in his out of the box newsletter last night which was written by Patrick Cox.

[pumpnass]

BTX always swings big just a make up from the bad market we have been having imo

[Liquid_Bull]

Big open... any news? I cant find any.

[Liquid_Bull]

Thanks for filling me in, sounds like it could be part of the scheme. BTX is fine, nice to see $7 already.

[Piecemaker]

Patrick Cox writes an expensive newsletter in which he identifies companies he believes are "Gamechangers". BTX and NNVC are but two of several. Below is an update he shared with subscribers last month (found this on another board). The link you posted reminded me of this, so I wondered if it's part of the problem he identifies below.



January 19, 2011

Don't Sell BioTime: Huge Profits Coming

Dear Breakthrough Technology Alert Reader,

I'm sending this unscheduled alert out to you today primarily to get the headline above circulating. The last couple of days have been extremely interesting, though a bit distressing. I'd like to tell you about them.

As I've told you in the past, breakthrough biotech companies are a favorite target of short attackers. Because new technologies are often confusing to people who do not take the time to study them, it is possible for unscrupulous groups to spread uncertainty and panic among many investors.

If you've spent any time at all on the message boards at investment sites, you know the kinds of nonsense that I'm talking about.

The more transformational a technology is, the easier it is to get people doubting it. Take, for example, NanoViricides (OTCBB: NNVC). This company's remarkable technology combines nano-sized polymer structures with biological ligands -- nanoviricides. The ligands "signal" to the target viruses that they are inside human cells. The viruses attack these nanoviricides and are, in turn, dismantled and harmlessly removed.

I know this sounds like science fiction.

In fact, the company has proven the technology over and over in conjunction with some of the world's most important scientists. It's real. It works, and it will revolutionize the way medical science deals with a broad range of viruses. Viruses, incidentally, are only now beginning to be truly understood. It appears, in fact, that they play roles in conditions we never suspected, ranging from obesity to chronic fatigue syndrome. So NanoViricides' future is vast.

Nevertheless, there is a minor industry based on convincing investors that NanoViricides is some sort of hoax. For a long time, if you did a Google search on the company name, the top paid search results were screaming claims that the company was a scam. If you searched my name, it often returned accusation that I was part of the NanoViricides scam.

I wish, by the way, that I did own part of NanoViricides. I am prohibited by my arrangement with Agora Financial.

Dr. Eugene Seymour told me that he had tried to contact Google about putting an end to this slander, but could never get a response. Google's informal corporate slogan, by the way, is "Don't be evil."

Anyway, there are several reasons that people might attack a company in this manner. Some are probably simply trying to sell a report about NanoViricides, or at least get credit card information from people foolish enough to fall for the trick.

Sometimes, however, these tactics are part of a broader short attack. Many of you know, in fact, that these short attacks are taking place because you have been offered money to "rent" your shares. I hear about it constantly, and this does not happen to just NanoViricides. The last time I reported it, Pro-Pharmaceuticals was being targeted.

In general, the greater the company's potential, the more attractive it is to short attackers. If a company has generated a lot of "buzz," it is likely that a lot of "traders" have decided to buy shares. These people often know nothing about the company's management, technology or market potential. They're just surfing trends.

As a result, groups that specialize in short attacks can manipulate them. These groups are expert at spreading rumors. They seem to have people planted on the boards who can say just the right thing at just the right time to trigger a stampede.

When I lived in Silicon Valley, I knew quite well the man who was then Steve Jobs' CFO. He frequently described his job in terms of warfare. I was skeptical at first, but he convinced me that a group of people were waging war against him and his company. If he didn't fight back, they would succeed.

Why would anybody attack a company run by Steve Jobs? They did so because sophisticated traders, as you know, can make money by driving a stock price down. In the age of the Internet, with the means to reach millions of investors, this has become a serious problem. Normally, I try to ignore these attacks because they usually don't hurt the companies they attack. They hurt the investors who sell their stock at low prices.

I've been hearing for some time about a massive short attack coming on BioTime (AMEX: BTX).

One source tells me that a group has spent $35 million so far in preparation for a big drop in price, at which time they would acquire the underpriced stock and fulfill their short orders, making a massive short-term profit. I don't worry about BioTime, because the company's IP and potential are so amazing.

I do worry about investors, however, who might fall prey to short attackers. The attackers are engaged even now in psychological warfare against BioTime. We've talked about this in the past, and I'm confident that you won't fall for it. Unfortunately, I've learned that my last weekly alert has been used to spread misinformation about BioTime to others.

Specifically, as you will recall, the headline was "A (No Rush) Sell Order & a Review of BioTime's Cardiovascular Therapy." I don't always write my headlines. I'm not very good at it, and other people on my team are. But I did write that one. Therefore, it distresses me to find out that it is being used by some to say that I've issued a sell order on BioTime, instead of API Technologies (OTCBB: ATNYD).

Since the headline of my alert is "outside the firewall," people apparently read my headlines and try to figure out what they mean without subscribing. Who knew?

Anyway, the rumor is spreading that I've issued a sell order on BioTime. In fact, as you know, I'm more excited than I've ever been about the company.

For years, Dr. Michael West has been making history, but it's been largely in the area of research. Finally, he has begun the process of bringing what amounts to a nonsurgical heart and vascular system transplant to the market. As I've previously explained, the market for this therapy is nearly unimaginable. Several years ago, I predicted that the company would someday rival the Big Pharma companies that dominate the medical scene today. I'm more convinced now than ever.

Anyway, you already knew this, but I wanted to make it clear. I'm putting this alert out so the headline will help counter the effort being made to cast doubt on BioTime.

Incidentally, tell your brokerage firm never to rent your shares of any stock.

Yours for transformational profits,

Patrick Cox
Special Offer: Save 55% Off Your Next Year of Breakthrough Technology Alert, Act Today!

[Liquid_Bull]

Not sure, fill me in. I just came across it while reading the news tabs next to the chart on the BTX google finance page.

[Piecemaker]

Is that "article" you cited part of the orchestrated short attack that Patrick Cox describes in his newsletter?

[DrStrangelove]

On the up side Petrobras is breaking like gangbusters from it's base in the low 30's. The deep water off Brazil and oil sands of Canada are looking better and better at over $100/per barrel.
But back to biotechs. They're all getting the crap kicked out of them right now, so we'll just have to wait until the dust settles. Until then, it's gold, gas and grain.

[DrStrangelove]

I think pumpnass is right, this is blood in the streets kind of dumping. Same thing is happening with rare earths, especially Great Western.

[pumpnass]

nice ;o)

[DrStrangelove]

I went ahead a picked up a few shares here.

[pumpnass]

soon we will be laughing in blue skies bud no doubt about it

[Liquid_Bull]

No worries. I think I am in close enough to this reversal point.

[pumpnass]

if you have the cash just buy more and avg down you won't have to many chances like this bud trust

[Liquid_Bull]

Biotime getting beat up... I jumped back in a little to early. Oh what a difference a few days of patience makes. Not the first time... probably not the last either :)

[DrStrangelove]

Looks like we've got some more pain to endure with this one. It's heading toward the 200 DMV.

[pumpnass]

just keep you eyes open bud you know how big the swings are here

[Liquid_Bull]

We agree that BTX is one to invest in. Can you send me your reasons not to invest in GERN, I am interested because I have 5,600 shares. Do you not invest in ACTC either? Any time I get to rationalize from someone elses perspective I take the opportunity. Thanks

[Liquid_Bull]

Very nice trade. I agree with your feelings on BTX. I laughed when I read that $2 price target.

http://www.americanbankingnews.com/2011/01/07/biologic-equity-research-initiates-coverage-on-biotime-inc-nyse-btx/

[investment_mgr]

Highly doubt it sees 2.

The acquisitions made by BTX are further pieces to the puzzle. West has a vision, and BTX is setting itself up perfectly imo to bring stem cells in mainstream medicine.

I think you are at the perfect buy point here with a W base shaping up on the short term chart and a retest of the handle on a major cup and handle formation.

Move back toward 10 likely. I bought this at .55 and sold at 9.60 as per my posts in another forum. Started back in this week.

Best,
IM

[investment_mgr]

I would not invest in GERN, I sold that for profits at 6 and change.


The big three imo are BTX, ISCO and CUR.

Best,
IM

[Liquid_Bull]

CTI & Glycosan deals:

They did pay 250k plus 261,959 shares for CTI.

And for Glycosan stockholders will receive a total consideration of around 332,906 BioTime common shares, and warrants to purchase around 206,612 additional BioTime common shares at an exercise price of $10 per share. BioTime will assume Glycosan’s obligations, which at January 31, 2011 totaled approximately $218,000.

I feel they bought some quality technology and West does well on his deals. These acquisitions combined with BioTime’s stem cell technologies, give BioTime and its subsidiaries a broad manufacturing platform.

The technology acquired from CTI uses peptides selected for their ability to adhere to diseased tissues. By coating or "painting" these peptides onto the surfaces of therapeutic cells using techniques that do not modify the cell physiology, CTI has produced tissue-specific and disease-specific cell modification agents with potential to take cell therapy products to a new level of performance.

Glycosan has been a leader in developing, manufacturing, and marketing proprietary biocompatible hydrogels that mimic the extracellular matrix (ECM). The ECM is an important and complex mixture of macromolecules that holds cells together in tissues and organs and performs many other important functions. The acquired products have the ability to support the growth and directed differentiation of stem cells and are designed as implantable, resorbable matrices for tissue engineering, regenerative medicine, and for research applications involving the laboratory culture of human cells.

These two acquisitions make BioTime stronger. The prices paid for each company do not seem pricey to me at all for what they are receiving. I am happy the pps pulled back under 7.50 because it was my buy back in target, but it can go lower, if it does I look at it as a gift to buy more shares at a discounted price. But it also seems to want to move up churning between $7 & $7.50 the past couple days. Buy in increments so either way it goes you make out, thats my plan. I will stick by my $15 target even though analysts at BioLogic Equity Research set a “sell” rating and a $2.00 price target on the stock, they just want the downtrend to continue so they get to buy shares on the cheap before the inevitable price appreciation and who are they? Either way I own shares of a company that in my opinion will be a leader in science and medicine. Like I posted before you have to own an interest in anything Lanza, Kierstead and West are involved in. I am currently researching Dr. Anthony Atala too. I hope this helps you decide to get in where you feel comfortable because this company looks to me like a winner. Time will tell

[Paulness]

I am very confused about this PR , if they acquired assets for 250 thousand why did they issue 261 thousand shares as part of deal wouldn't that make the deal worth over 2 million at the time of the PR. Hmmm. I sold at $8.80 but thinking that this may relax a lot more because of this type of PRs. I am looking to get in at a lower PPS now obviously buying low selling high is the way to make money .

ALAMEDA, Calif. (AP) -- BioTime Inc. said Friday it has acquired substantially all the assets from biotech company Cell Targeting Inc. for $250,000, a move aimed at bolstering its slate of embryonic stem-cell therapy products.

BioTime issued 261,959 common shares as part of the deal and its stock fell 62 cents, or 7.6 percent, to $7.51 on Friday

[pumpnass]

no i have been holding and adding for a long time and will be pasing it down to my kids in the year to come ;o)

[DrStrangelove]

Ok. You talked me into it. I just bought STEM. Probably shares you sold! LOL

[pumpnass]

so was ACTC'S before the big move and trust bud STEM is way over due

[DrStrangelove]

Chart on STEM looks kinda tragic thou.

[pumpnass]

STEM is another one ;o)

[DrStrangelove]

ISCO is the only other stem cell but it's not doing too hot either.

[Liquid_Bull]

Bought 1000 @ 7.43 yesterday. I will sell half when it hits $15 and ride the free shares.... For now, I just hope the tide turns sooner rather than later. If your into stem cells you have to put your chips on GERN & Keirstead, ACTC & Lanza and BTX & West. Anyone else have any other must own scientist or company not mentioned here in their portfolio?

[DrStrangelove]

I'm in.